287 results about "Brain damage" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention discloses a method, a system and equipment for evaluating the treatment effect of CGRP on epilepsy or brain injury caused by epilepsy. It is found for the first time that CGRP inhibits expression of P2RX7 by inhibiting a JAK-STAT1 pathway so as to play a role in treating epilepsy or brain injury caused by epilepsy. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CGRP on the epilepsy or the brain injury caused by the epilepsy for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the epilepsy or the brain injury caused by the epilepsy, and a clinician is guided to formulate an individualized treatment scheme for the patient.

The present invention belongs to the field of rehabilitation therapy technology and discloses a longitudinal analysis method and system for magnetic resonance imaging data of mild brain injury. The method extracts BOLD signals from the magnetic resonance imaging data of subjects; constructs a symmetric positive definite sparse brain functional connectivity network set of subjects based on sparse inverse covariance matrix estimation; determines the brain functional connectivity network dictionary and sparse coefficient matrix in kernel space based on Riemannian manifold sparse coding; performs spatial distribution analysis of brain functional connectivity atomic networks; and performs longitudinal analysis of magnetic resonance imaging data of mild brain injury. By analyzing the differences in the spatial distribution of these highly present brain functional connectivity atomic networks in the brain, the present invention digs out brain functional connectivity imaging markers for distinguishing the three mild brain injury rehabilitation treatment stages: acute phase, subacute phase, and complete recovery, thereby realizing longitudinal analysis of the mild brain injury rehabilitation process.

The invention provides a brain injury prediction method and prediction system based on a multivariate feature fusion framework, and relates to the technical field of deep learning. In order to solve the problem that dynamic characteristics and static characteristics cannot be effectively fused when multivariate data damage prediction is carried out by adopting a nonlinear regression method in the prior art, dynamic characteristic data, static characteristic data, dynamic mechanical effect parameters, static influence effect parameters and brain damage degree data under various working conditions of a vehicle are obtained. A dynamic mechanical effect parameter is used as output to train a dynamic prediction model, accurate extraction of a dynamic feature time sequence rule can be ensured, a static influence effect parameter is used as output to ensure extraction of a static feature structured rule, and finally a dynamic feature vector and a static feature vector are used as input of a fusion prediction model. Fusion of a dynamic time sequence rule and a static structured rule is achieved, it is ensured that the two types of features are fully fused, and the prediction result is more accurate.

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

To provide 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase.SOLUTION: Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the present invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating nNOS-associated diseases and disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as amyotrophic lateral sclerosis, cerebral palsy, stroke / ischemic brain injury, and migraine headaches.SELECTED DRAWING: Figure 1

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and / or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

The application discloses a wearable brain injury local temperature control treatment device and belongs to the technical field of brain injury treatment. The device is provided with a mounting bottom plate, a rotating frame, a waste glue storage box, a moving strip, a glue coating scraper and an adjusting screw sleeve. The connecting top strip is tightly arranged on the top of the adjusting screw sleeve. The minimum distance between the glue coating scraper and the mounting bottom plate is limited. An appropriate amount of gel is applied on the edge of the temperature control sheet. The moving strip is pushed to drive the glue coating scraper to move on the top of the mounting bottom plate. The glue coating scraper pushes the gel to be applied on the top of the temperature control sheet. The gel can be uniformly applied on the surface of the temperature control sheet. The gel on the surface of the temperature control sheet is not uniformly applied. The contact between the temperature control sheet and the skin is not uniform. The heat transfer and distribution are affected. When the glue coating scraper passes through the temperature control sheet, the excess gel is pushed to flow from the top of the trapezoidal inclined block to the waste glue storage box. The excess gel is prevented from being left on the mounting bottom plate, so that the surface of the mounting bottom plate is not sticky.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention discloses a novel neurophotoelectrode, comprising: a chip for vertically emitting modulated laser light to an electrode structure; and an electrode structure with its tip positioned away from the chip, capable of simultaneously transmitting optical and electrical signals. Both the chip and the electrode structure utilize a flexible silicon substrate, are coupled together, and encapsulated within a flexible material. This novel neurophotoelectrode is a new brain electrode structure combining a silicon photonic waveguide (PIC) with a flexible Utah electrode. Besides transmitting and receiving neuronal electrical signals, it can achieve deeper stimulation via laser light. Furthermore, utilizing the PIC chip's MZ modulation technology, it can achieve targeted and quantitative optical signal stimulation based on feedback signals. Its flexibility reduces brain damage, while simultaneously achieving photoelectric stimulation, increasing stimulation depth, and expanding its application scope, demonstrating broad application prospects.

The invention discloses an application of abscisic acid in preparation of a medicine for improving secondary brain injury after cerebral hemorrhage, the abscisic acid can relieve neuroinflammation and improve neurological function recovery by repairing microglial cell lysosome functions, enhancing phagocytic ability and promoting hematoma removal, and a new medicine strategy is provided for cerebral hemorrhage treatment.

The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone / sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone / sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

The invention discloses a polyarginine nano-particle as well as a preparation method and application thereof. The preparation method comprises the following steps: polymerizing ornithine-carboxylic anhydride (NCA) serving as a monomer with leucine to obtain a diblock polymer, or polymerizing the ornithine-carboxylic anhydride monomer, and then performing guanidination treatment and self-assembly to obtain the polyarginine nanoparticles. The polyarginine nano-particles prepared by the invention can be combined with free nucleic acid released by injured tissues or cells in traumatic brain injury (TBI) to remove the free nucleic acid and prevent downstream immune response reaction, so that the proinflammatory factor level is remarkably reduced, and the purposes of relieving inflammation and treating TBI are achieved; compared with the traditional cationic amino acid (polylysine), the polyarginine material adopted by the invention can effectively improve the prognosis of TBI patients. Therefore, the invention provides the nano material with remarkably improved DNA binding capacity and treatment effect, and the nano material has important significance in treatment of traumatic brain injury.

To provide methods for detecting inflammasome proteins as biomarkers of neurological disorders.SOLUTION: The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described. Presented herein are inflammasome components useful as biomarkers with high sensitivity and specificity for various neurological or psychiatric conditions and methods of their use.SELECTED DRAWING: None

The invention discloses a substituted aromatic heterocyclic compound containing a spiro skeleton as well as a preparation method and application thereof, and relates to the field of medicinal chemistry, in particular to the substituted aromatic heterocyclic compound containing the spiro skeleton or pharmaceutically acceptable salt of the substituted aromatic heterocyclic compound, a necessary composition containing the compounds and medical application of the substituted aromatic heterocyclic compound. The invention relates to an application of a monoacylglyceridase inhibitor, in particular to application of the monoacylglyceridase inhibitor as a monoacylglyceridase (MAGL) inhibitor in preparation of drugs for preventing and / or treating MAGL-related diseases. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and other related diseases.

The application discloses a nano guanido drug system and a preparation method and application thereof, and relates to the technical field of medicine, in particular to a GCOF DHM @CAQK platform, can efficiently deliver drugs to a TBI injury site, can accumulate in a TBI brain injury area, can inhibit neuroinflammation, oxidative stress and protect neuron cells after TBI, can precisely intervene in secondary injury of TBI, and provides a new strategy for improving the prognosis of patients.

The present invention provides the use of the small molecule compound 2-D08 in the preparation of a drug for treating or preventing demyelinating diseases. As a small molecule compound, 2-D08 has a small molecular weight and is easily permeable through the blood-brain barrier to exert central pharmacodynamic effects. Moreover, the chemical synthesis method of 2-D08 is also very mature, which is conducive to reducing the preparation cost of drugs for treating demyelinating diseases, thereby alleviating the medical expenses of patients to a certain extent. 2-D08 can promote the regeneration of myelin sheaths of spinal cord axons, significantly improve the motor ability and nerve function recovery of mice, and is expected to become a disease-modifying treatment drug targeting the origin of brain damage in MS patients, with brain permeability and ion channel selectivity, and has very broad application prospects.

The present disclosure relates to a compound of formula (I) which is in crystalline Form 1, characterized by having a powder X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 3.3, 10.0, 20.1, 21.7, and 25.0. The present disclosure also relates to processes for its preparation, as well as a medicament and a pharmaceutical composition comprising it. The present disclosure further concerns the crystalline Form 1 of compound of formula (I) for use as a medicine and more particularly in the prevention and / or in the treatment of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.

The application discloses a brain injury identification method and an identification system. The identification system identifies the injury of a patient according to the identification method. The identification method comprises the following steps: firstly, the electrical impedance tomography (EIT) of the brain of the patient is performed to obtain the EIT image of the brain of the patient; then, the region with abnormal resistivity distribution in the EIT image of the brain is taken as a reference for scanning of a near-infrared spectrometer, and a scanning path of the near-infrared spectrometer is planned; finally, the near-infrared spectrometer is scanned along the scanning path, and the lesion range and the lesion type are determined according to the obtained near-infrared spectral data. The electrodes need not be arranged on the whole head of the patient, and the automatic and rapid identification of the lesion range and the nature of the brain injury is realized.